100PercentFedUp.com By Danielle
The U.S. Food and Drug Administration (FDA) on August 3, 2023, approved Merck’s ERVEBO Zaire ebolavirus vaccine for individuals 12 months of age and older.
The vaccine was previously approved for individuals 18 years of age and older.
Merck receives FDA approval for Ebola vaccine https://t.co/Tnm4dVJ3Wz pic.twitter.com/Lfubls9VSf
— Reuters (@Reuters) December 20, 2019
Merck announced:
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older. The vaccine was previously approved for use in individuals 18 years of age and older. ERVEBO does not protect against other species of Ebolavirus or Marburgvirus and the duration of protection conferred by ERVEBO is unknown. The effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown. ERVEBO includes a contraindication for individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including rice protein…
